Anagenics Limited (AN1.AX)

0.0080 0.0000 (0.00%) 收市：02:05PM AEST

Anagenics Limited

55 Clarence Street
Suite 204 Level 2
Sydney, NSW 2000
Australia
61 2 9221 6830
https://anagenics.com

版塊: Consumer Defensive
行業: Household & Personal Products
全職員工: 

高階主管

名稱	頭銜	支付	行使價	出生年份
Ms. Karen Matthews	CEO & Director	19.17k	無	無
Mr. Matthew Dudek	Chief Financial & Governance Officer and Company Secretary	282.67k	無	無
Mr. Scott Mitchell Greasley	Executive Director	1.15M	無	無
Mr. Dominic Burg	Chief Operating Officer	無	無	無
Dr. Graham Robertson	Head of Research & Development	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 AUD。

描述

Anagenics Limited operates as a health and beauty tech company in Australia, New Zealand, and internationally. It develops and sells FGF5 inhibitor formulations; over-the-counter (OTC), cosmetic antiaging, and longevity targeting products; and imports and distributes international and local skin care and wellbeing products under the Thalgo, Hydro Peptide, Comfort Zone, Priori, and Inika Organic brand names. The company also develops, manufactures, and markets beauty and wellness brands comprising Uspa and evolis. It offers its products through various channels, including clinics, retail stores, wholesale pharmacy and spa/salons, online ecommerce, and cross border export markets. The company was formerly known as Cellmid Limited and changed its name to Anagenics Limited in December 2021. Anagenics Limited was incorporated in 2004 and is based in Sydney, Australia.

公司管治

截至 無 止，Anagenics Limited 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。